A:

In 1982,

The U.S. Food and Drug Administration (FDA) recognized the lack of incentive for pharmaceutical companies to develop cures for rare diseases and established the Office of Orphan Product Development. This branch of the FDA provides incentives to companies that work toward curing rare diseases by exercising the rights given to them under the Orphan Drug Act of January 1983. One type of incentive is the orphan drug status, which provides tax reductions and the exclusive right to develop the cure for a specific condition for a period of seven years to companies attempting to cure rare diseases.

Developing drugs to treat the vast number of diseases in the world is a line of business that can lead to massive fortunes, but unfortunately not all developed drugs become the golden ticket. In the world pharmaceuticals, the largest amount of money can be made by developing drugs that become the standard for curing common diseases.

From a business perspective, having a large market ensures that a company can quickly recuperate the cost of development and can also realize the largest possible gain. For this reason, there is little incentive for pharmaceutical companies to develop cures for rare diseases - those that affect fewer than 200,000 people in the United States - because the small market and high cost associated with finding these types of cures discourages these companies from entering this market.

For related reading, check out Measuring The Medicine Makers.

RELATED FAQS

  1. What does it mean when a company in the drug sector has orphan drugs?

    Understand what it means when a company in the pharmaceutical industry has drugs within its portfolio that are designated ...
  2. What is a private secondary market?

    Read about private secondary markets, also called private resale markets, which allow for liquid equity investments outside ...
  3. What are the ethical arguments against government subsidies to companies like Tesla?

    Learn about the ethical argument behind government subsidies.
  4. Has deregulation helped or hurt the profitability of companies in the telecommunications ...

    Read about the impact of deregulation on the U.S. telecommunications sector, particularly with regards to the profits of ...
RELATED TERMS
  1. Early Warning Tests

    A series of financial ratios and other performance criteria used ...
  2. Correction Notice

    A notice indicating that a process or application contains errors ...
  3. Qualified Longevity Annuity Contract

    A Qualified Longevity Annuity Contract (QLAC) is a deferred annuity ...
  4. Structured Transaction

    A series of transactions that could have been treated as a single ...
  5. The New Deal

    A series of domestic programs designed to help the United States ...
  6. Assigned Risk

    A risk that an insurance company is required to provide coverage ...

You May Also Like

Related Articles
  1. Investing Basics

    What does it mean when a company in ...

  2. Personal Finance

    Why Best Buy Failed in China

  3. Entrepreneurship

    Lockheed Martin Is Tight With The US ...

  4. Fundamental Analysis

    Is Baidu a Real Threat to Google?

  5. Economics

    The Economics Of Solar Power

Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!